Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

Leukemia. 2019 Aug;33(8):2102-2104. doi: 10.1038/s41375-019-0437-5. Epub 2019 Mar 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Central Nervous System Neoplasms / immunology
  • Central Nervous System Neoplasms / therapy*
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Receptors, Antigen, T-Cell / immunology*
  • Recurrence

Substances

  • CD19-specific chimeric antigen receptor
  • Receptors, Antigen, T-Cell